What Is MOTS-c? Benefits, Human Studies and the Evidence

Apex Laboratory / MOTS-c explained

Most confusion starts with a small change in wording: exercise increased MOTS-c becomes MOTS-c works like exercise. Those are different claims. This guide separates what the molecule is, what researchers actually changed in each study, and what remains unknown about administering it to people.

What does MOTS-c mean, and where does it come from?

The name refers to a mitochondrial open reading frame within the 12S ribosomal RNA region. An open reading frame is a stretch of genetic sequence that can encode a peptide. The corresponding mitochondrial gene is MT-RNR1; MT-RNR2 is the separate 16S rRNA gene. The 2015 discovery paper described the 16-residue sequence and its metabolic effects in experimental systems.

One sequence. Sixteen amino acids.

The letters below identify the reported human MOTS-c sequence, in order.

1. M1
2. R2
3. W3
4. Q4
5. E5
6. M6
7. G7
8. Y8
9. I9
10. F10
11. Y11
12. P12
13. R13
14. K14
15. L15
16. R16

12S rRNA · MT-RNR1The mitochondrial region containing the reading frame.

MRWQEMGYIFYPRKLRThe sequence studied as MOTS-c; a modified analogue is a different material.

“Mitochondrial-derived” describes the genetic origin. It does not mean a supplied peptide automatically reaches every mitochondrion, repairs mitochondrial DNA, or replenishes a clinically defined deficiency. The early MOTS-c review and review of mitochondrial-derived peptides in aging and disease explain the broader signaling hypothesis.

Three different things can be called “MOTS-c research”

This distinction matters more than counting papers. A randomized study can measure MOTS-c while the actual treatment is exercise, heat or another drug. Read the intervention and outcome fields before treating “human study” as evidence for administered MOTS-c.

What are the proposed benefits of MOTS-c?

The best-known claims concern glucose regulation, body fat, muscle function and aging. The biological rationale comes mainly from experimental work; the result changes with the model, outcome and material.

Metabolism
2015–2019

Insulin sensitivity and diet-related weight changes

Lee and colleagues reported protection against age- and diet-associated insulin resistance and diet-induced obesity in mice. A 2019 mouse metabolomics study examined changes in lipid-related pathways alongside insulin sensitivity. These findings do not establish a human weight-loss effect or selective reduction of belly fat.

Muscle
2021

Physical capacity and atrophy-related signaling

Reynolds and colleagues studied physical performance in young, middle-aged and old mice, including treatment begun late in life. The same paper’s human component measured responses to exercise. A separate myostatin study combined human blood correlations, cultured mouse muscle cells and diet-induced obese mice. It did not demonstrate increased human muscle mass from taking MOTS-c.

Immune biology
2026

A broader role than energy metabolism

A 2026 study investigated antibacterial and immune-signaling functions in bacterial, cell and mouse systems, including human monocytes. This expands the research questions around MOTS-c. It is not a clinical demonstration that MOTS-c treats infection.

Reviews of MOTS-c stress signaling, aging-related mitochondrial peptides and metabolic research offer useful context. Reviews organize existing findings; they do not add a new treated patient population.

How does MOTS-c connect to AMPK?

AMPK is an enzyme complex involved in how cells respond to energy stress. The discovery experiments linked MOTS-c to changes in folate and purine metabolism, accumulation of the intermediate AICAR, and AMPK activation. That is a proposed experimental pathway, not proof of a single, fully established receptor-to-benefit mechanism in people.

From a stress response to a gene response

1. Metabolic stressResearchers challenged cells with conditions such as glucose restriction.
2. Nuclear movementMOTS-c moved into the nucleus in an AMPK-dependent manner.
3. Gene regulationThe study examined stress-response genes and interaction with NRF2.

What do human MOTS-c studies actually show?

Human evidence is real, but much of it concerns the body’s own peptide. The following studies illustrate the difference between measuring MOTS-c and administering it.

On a narrow screen, scroll the table horizontally to read every study column.

These findings support questions about MOTS-c as a marker or mediator of adaptation. They cannot establish an effective human dose, a predictable feeling after use, or that a laboratory preparation replaces exercise. A measured increase may accompany several changes; identifying which change causes an outcome requires a different experiment.

What about the K14Q genetic variant?

K14Q means the lysine at position 14 is replaced by glutamine. A 2021 analysis of three cohorts totaling 27,527 people linked the mitochondrial m.1382A>C variant to higher type 2 diabetes prevalence in men, with physical-activity differences in one cohort. It also compared native and variant peptides experimentally. This does not show that supplying MOTS-c prevents diabetes.

A separate study examined muscle-fiber composition, strength and athlete-group frequencies in Japanese participants. A genotype association is not a treatment trial and should not become a claim that more MOTS-c uniformly improves athletic performance. The 2023 review of mitochondrial microproteins and variants places these findings in context.

Are there clinical trials of MOTS-c or CB4211?

Yes, there are relevant registry records, but the material and status need to stay attached to each one. The entries below were checked on September 8, 2026. Registry information is supplied by the responsible party; a listing does not independently verify that recruitment is occurring or establish a successful result.

Native-name
registration

MOTS-MET: a registered plan, without posted results

NCT07505745, submitted by Hudson Biotech, names MOTS-c and placebo for adults with prediabetes and overweight or obesity. The record describes a phase 2 study with an estimated enrollment of 120, reports “Recruiting,” and was last updated on April 1, 2026. No study results were posted at this review.

It would be inaccurate to say no MOTS-c intervention is registered. It would also be inaccurate to use this entry as completed human efficacy or safety evidence, or as an independently confirmed treatment option.

Modified
analogue

CB4211: a different investigational material

NCT03998514 is CohBar’s phase 1a/1b study of CB4211 in healthy non-obese participants and participants with nonalcoholic fatty liver disease. It reports completion on April 19, 2021 and actual enrollment of 88. The registry has no posted results and was last updated on May 11, 2021.

CohBar describes CB4211 as an analogue of MOTS-c. A completed early trial is a different claim from an approved therapy. Findings about this development analogue do not establish the performance of a native MOTS-c reagent. The distinction also matters when reading summaries that simply call CB4211 “the human MOTS-c trial.”

The broad registry search also returned studies measuring MOTS-c while investigating exercise, anesthesia or other treatments, plus unrelated matches. Counting all of those as trials of administered MOTS-c would exaggerate the evidence. The review of mitochondrial peptides in aging and healthspan is useful background, while the direct registry entries above provide the dated status.

Side effects, approval status and dosing claims

These sources do not establish a reliable human side-effect rate or an evidence-based self-use schedule for native MOTS-c. Online reports about energy, appetite, sleep or hair changes cannot separate the peptide from other exposures, product identity, expectations and underlying conditions. Lack of a documented adverse event is not evidence that an effect cannot occur.

In its July 2026 scientific presentation, FDA stated that MOTS-c free base and acetate were not components of an FDA-approved drug. The review described missing human effectiveness and safety information and concerns about impurities, aggregation and potential immunogenicity. This is a dated assessment of specified substances; a compounding discussion or advisory vote is not drug approval.

The same FDA assessment distinguished rapid breakdown in an in-vitro human-blood experiment from human pharmacokinetic data. A laboratory degradation experiment cannot supply a clinical half-life, dosing interval or cycling schedule. Amounts used in mice and protocols for a modified analogue are not substitutes for those missing data.

Apex’s MOTS-c material is a research-use-only reagent. A product listing, a molecular sequence and a laboratory report do not make it a medicine or establish suitability for human administration.

What should a researcher check about the material?

Start with the identity used in the actual experiment. “MOTS-c,” the K14Q variant and CB4211 do not identify the same preparation. For the native human sequence, retain the amino-acid order and check the stated terminal and salt form. A catalog molecular weight is a reference value, not a measurement of the particular lot.

The MOTS-c (Human) product page provides current material configurations and links to applicable records. Read the issuer and lot on the record itself through the Lab Verified library. For the meaning of separate measurements, see how to read a peptide COA and what HPLC purity measures.

Frequently Asked Questions

What is MOTS-c peptide?

MOTS-c is a 16-amino-acid peptide encoded in a short reading frame within mitochondrial 12S rRNA, the MT-RNR1 region. It is studied in cellular stress, metabolism and muscle biology. Its genetic origin does not establish that a supplied preparation restores mitochondrial function in people.

Does MOTS-c burn belly fat?

Mouse experiments reported diet-related weight and metabolic findings. The studies discussed here do not establish that administered native MOTS-c reduces abdominal fat in people. Human exercise studies that measure endogenous MOTS-c are not trials of taking the peptide.

Are there human clinical trials of MOTS-c?

The MOTS-MET registry entry names MOTS-c and reports a planned phase 2 study, but no results were posted when checked on September 8, 2026. Other human studies often measure endogenous MOTS-c while testing exercise or another intervention. The separate completed CB4211 trial tested a modified analogue.

Is CB4211 the same as MOTS-c?

No. CB4211 is a development analogue derived from MOTS-c. Its early human trial tested that investigational material and protocol. Results or safety statements about it cannot be assigned to a native MOTS-c research reagent.

What are the side effects of MOTS-c, including hair loss?

These sources do not establish a reliable human side-effect profile for administered native MOTS-c or a causal answer about hair loss. Online experiences cannot resolve product identity, other exposures or underlying conditions. Missing data should not be read as evidence of safety.

How long should someone stay on MOTS-c?

An evidence-based self-use duration or cycling schedule is not established by these studies. Mouse experiments, natural blood-level changes and protocols for modified analogues do not provide a validated human schedule for native MOTS-c.

Is MOTS-c FDA approved?

FDA’s July 2026 scientific presentation stated that MOTS-c free base and acetate were not components of an FDA-approved drug. A compounding discussion is not product approval. Apex’s MOTS-c is a research-use-only reagent, not an approved medicine.

Does a MOTS-c COA prove that it works?

No. A report can document specific identity, chromatographic-area or active-content findings for a named material and lot. Those analytical results do not establish a biological response, a human benefit or suitability for administration.

Continue with the specific question

The SS-31 / elamipretide guide covers a different peptide and a different development history; mitochondrial relevance does not make the two interchangeable. The longevity and bioregulator research hub places these materials alongside other research families.

References

Primary studies, commentaries and reviews are identified separately in the discussion. Registry status and the FDA scientific assessment were checked on September 8, 2026. A published study title can describe a proposed benefit more broadly than the model actually establishes.

1. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell metabolism. 2015. PMID 25738459.
2. Lee C et al. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free radical biology & medicine. 2016. PMID 27216708.
3. Kim SJ et al. Mitochondrially derived peptides as novel regulators of metabolism. The Journal of physiology. 2017. PMID 28574175.
4. Benayoun BA et al. MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus. BioEssays : news and reviews in molecular, cellular and developmental biology. 2019. PMID 31378979.
5. Lee C et al. Nuclear transcriptional regulation by mitochondrial-encoded MOTS-c. Molecular & cellular oncology. 2019. PMID 31131297.
6. Kim SJ et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiological reports. 2019. PMID 31293078.
7. Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature communications. 2021. PMID 33473109.
8. Kumagai H et al. MOTS-c reduces myostatin and muscle atrophy signaling. American journal of physiology. Endocrinology and metabolism. 2021. PMID 33554779.
9. Kim SJ et al. Mitochondrial-derived peptides in aging and age-related diseases. GeroScience. 2021. PMID 32910336.
10. Miller B et al. Mitochondria-derived peptides in aging and healthspan. The Journal of clinical investigation. 2022. PMID 35499074.
11. Zempo H et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging. 2021. PMID 33468709.
12. Kumagai H et al. The MOTS-c K14Q polymorphism in the mtDNA is associated with muscle fiber composition and muscular performance. Biochimica et biophysica acta. General subjects. 2022. PMID 34728329.
13. Gao Y et al. MOTS-c Functionally Prevents Metabolic Disorders. Metabolites. 2023. PMID 36677050.
14. Kumagai H et al. Novel Insights into Mitochondrial DNA: Mitochondrial Microproteins and mtDNA Variants Modulate Athletic Performance and Age-Related Diseases. Genes. 2023. PMID 36833212.
15. Kim KH et al. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell metabolism. 2018. PMID 29983246.
16. Xing L et al. Mitochondrial-derived peptide MOTS-c activates metabolic signaling but blunts reparative function in human mesenchymal stromal cells. Inflammation and regeneration. 2026. PMID 42324588.
17. Dieli-Conwright CM et al. Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Scientific reports. 2021. PMID 34413391.
18. von Walden F et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. Journal of applied physiology (Bethesda, Md. : 1985). 2021. PMID 34351816.
19. Elhusseiny R et al. Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization. Medicine and science in sports and exercise. 2025. PMID 40674654.
20. Rice MC et al. MOTS-c is a mitochondrial-encoded interferon-linked host defense peptide. eLife. 2026. PMID 42611943.